Brought to you by 
Cognoa licenses Stanford's AI behavioral intervention technology for its ASD digital diagnostic device
22 Apr 2022
Executive Summary
Cognoa exclusively licensed Stanford University School of Medicine's wearable artificial intelligence (AI)-powered behavioral intervention technology to accelerate development and worldwide commercialization of the company's own digital diagnostic and therapeutic device for children with autism spectrum disorder (ASD), a developmental disability that can cause significant social, communication, and behavioral challenges.
Deal Industry
- Medical Devices
-
Medical Devices
- Diagnostic Equipment & Supplies
- Monitoring Equipment & Devices
- Rehabilitation Equipment and Devices
-
Digital Health
- Artificial Intelligence
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cognoa licenses Stanford's AI behavioral intervention technology for its ASD digital diagnostic device
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice